Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $4.10 million. The enterprise value is -$9.25 million.
| Market Cap | 4.10M |
| Enterprise Value | -9.25M |
Important Dates
The next estimated earnings date is Friday, August 7, 2026, before market open.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 3.91 million shares outstanding. The number of shares has increased by 4,135.82% in one year.
| Current Share Class | 3.91M |
| Shares Outstanding | 3.91M |
| Shares Change (YoY) | +4,135.82% |
| Shares Change (QoQ) | +110.48% |
| Owned by Insiders (%) | 4.70% |
| Owned by Institutions (%) | 4.52% |
| Float | 3.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.32 |
| P/TBV Ratio | 0.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.02, with a Debt / Equity ratio of 0.06.
| Current Ratio | 10.02 |
| Quick Ratio | 9.96 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -124.41% and return on invested capital (ROIC) is -75.68%.
| Return on Equity (ROE) | -124.41% |
| Return on Assets (ROA) | -66.19% |
| Return on Invested Capital (ROIC) | -75.68% |
| Return on Capital Employed (ROCE) | -73.88% |
| Weighted Average Cost of Capital (WACC) | 3.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.39M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.27% in the last 52 weeks. The beta is -0.10, so REVB's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | -88.27% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 3.00 |
| Relative Strength Index (RSI) | 50.67 |
| Average Volume (20 Days) | 48,033 |
Short Selling Information
The latest short interest is 26,240, so 0.67% of the outstanding shares have been sold short.
| Short Interest | 26,240 |
| Short Previous Month | 34,510 |
| Short % of Shares Out | 0.67% |
| Short % of Float | 0.76% |
| Short Ratio (days to cover) | 0.45 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.07M |
| Pretax Income | -9.87M |
| Net Income | -21.50M |
| EBITDA | -10.04M |
| EBIT | -10.07M |
| Earnings Per Share (EPS) | -$15.33 |
Balance Sheet
The company has $14.11 million in cash and $759,044 in debt, with a net cash position of $13.35 million or $3.42 per share.
| Cash & Cash Equivalents | 14.11M |
| Total Debt | 759,044 |
| Net Cash | 13.35M |
| Net Cash Per Share | $3.42 |
| Equity (Book Value) | 12.99M |
| Book Value Per Share | 3.32 |
| Working Capital | 12.79M |
Cash Flow
In the last 12 months, operating cash flow was -$8.69 million and capital expenditures -$71,879, giving a free cash flow of -$8.76 million.
| Operating Cash Flow | -8.69M |
| Capital Expenditures | -71,879 |
| Depreciation & Amortization | 27,040 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.76M |
| FCF Per Share | -$2.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
REVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4,135.82% |
| Shareholder Yield | -4,135.82% |
| Earnings Yield | -524.02% |
| FCF Yield | -213.50% |
Analyst Forecast
The average price target for REVB is $19.25, which is 1,733.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.25 |
| Price Target Difference | 1,733.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 28, 2026. It was a reverse split with a ratio of 1:4.
| Last Split Date | Jan 28, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |